Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Melorask Pharma AB
AB
Active
Org 5593492969
Bettina Olssons Väg 67
General medical practice activities · NACE 8621
Est. 2021
1-4 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 206K
-85% vs 2023
EBITDA margin
-61.9%
-152% vs 2023
Equity ratio
90.5%
Financial strength
Net profit 2024
SEK -129K
-168% vs 2023
EBITDA — year on year
SEK millions
0M
0M
1M
1M
1M
0M
2021
1M
+100%
2022
0M
-100%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
SEK 206K
-85%
EBITDA
SEK -127K
-152%
Net profit
SEK -129K
-168%
Total assets
SEK 381K
-30%
Equity
SEK 345K
-27%
Employees
—
—
Company information
Legal name
Melorask Pharma AB
Org number
5593492969
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
29 november 2021
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Konsulttjänst inom läkemedelsföretag och sjukvården.
Contact
Address
Bettina Olssons Väg 67
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in General medical practice activities
Companies in Malmö
All Sweden companies
Revenue
SEK millions
0M
1M
1M
2M
2M
0M
2021
2M
2022
1M
2023
0M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2021
1M
2022
0M
2023
0M
2024
Income statement
SEK thousands
Item
2021
2022
2023
2024
Revenue
—
1 539
1 412
206
Staff expenses
—
−602
−379
−58
EBITDA
−12
582
245
−127
Depreciation & amort.
—
—
—
—
EBIT
−12
582
245
−127
Net financials
0
−0
−1
−2
Profit before tax
−12
582
245
−129
Tax
—
−118
−53
—
Net profit
−12
464
191
−129
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
Total assets
17
770
545
381
Equity
13
478
474
345
Long-term debt
—
—
—
—
Short-term debt
4
292
71
36
Total debt
4
292
71
36
Financial ratios
5-year trend
EBITDA margin
-61.9%
This company
15.8%
Market median
-492% vs market
2021
2024
Equity ratio
90.5%
This company
38.2%
Market median
+137% vs market
2021
2024
Return on equity
-37.5%
This company
18.4%
Market median
-304% vs market
2021
2024
Net profit margin
-62.8%
This company
8.1%
Market median
-875% vs market
2021
2024
Asset turnover
0.54×
This company
1.12×
Market median
-52% vs market
2021
2024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
2021
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-11-29 – 2021-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
LA
Lina Anna Elisabeth Nordström
Board of Directors
2021
—
—
RF
Rim Fayad
Board of Directors
2022
—
—
LH
Lars Hugo Viking Rillner
Deputy Board Member
2021
—
—
AA
Ali Al-Dabbagh
Deputy Board Member
2022
—
—
HD
Henrik Daniel Karlsson
Deputy Board Member
2021
—
—
MJ
Mikaela Jenni Berglund
Deputy Board Member
2021
—
—
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Melorask Pharma AB also hold positions in
0
other companies.
Person
Role here
Other companies
Lina Anna Elisabeth Nordström
Board of Directors
0 companies
Rim Fayad
Board of Directors
0 companies
Lars Hugo Viking Rillner
Deputy Board Member
0 companies
Ali Al-Dabbagh
Deputy Board Member
0 companies
Henrik Daniel Karlsson
Deputy Board Member
0 companies
Mikaela Jenni Berglund
Deputy Board Member
0 companies